Laddar...
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
PURPOSE OF REVIEW: Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1–2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure o...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2014
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4124617/ https://ncbi.nlm.nih.gov/pubmed/24335709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000016 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|